Amphastar Pharmaceuticals Inc. (AMPH) Given a $21.00 Price Target by Jefferies Group Analysts
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) received a $21.00 price target from equities researchers at Jefferies Group in a report issued on Wednesday. The firm presently has a a “buy” rating on the stock. Jefferies Group’s target price would suggest a potential upside of 2.89% from the stock’s current price.
Other analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a report on Tuesday, October 11th. Needham & Company LLC raised their target price on shares of Amphastar Pharmaceuticals from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, August 9th. BMO Capital Markets restated a “hold” rating and set a $17.00 target price on shares of Amphastar Pharmaceuticals in a report on Tuesday, August 9th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $23.00 target price (up from $22.00) on shares of Amphastar Pharmaceuticals in a report on Wednesday, September 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Amphastar Pharmaceuticals currently has an average rating of “Buy” and an average price target of $20.17.
Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) opened at 20.41 on Wednesday. Amphastar Pharmaceuticals has a 12-month low of $10.50 and a 12-month high of $21.53. The stock’s 50 day moving average price is $18.78 and its 200-day moving average price is $17.02. The firm has a market capitalization of $920.92 million, a P/E ratio of 66.27 and a beta of 1.86.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Tuesday, November 8th. The company reported $0.14 EPS for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.11. Amphastar Pharmaceuticals had a net margin of 7.75% and a return on equity of 6.95%. The business had revenue of $64.20 million for the quarter, compared to analyst estimates of $65.12 million. During the same quarter last year, the business earned ($0.01) earnings per share. The business’s revenue for the quarter was up .5% on a year-over-year basis. On average, equities analysts expect that Amphastar Pharmaceuticals will post $0.37 EPS for the current year.
In related news, insider Jason B. Shandell sold 5,987 shares of the firm’s stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $18.86, for a total value of $112,914.82. Following the completion of the transaction, the insider now owns 202,961 shares of the company’s stock, valued at approximately $3,827,844.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jack Y. Zhang sold 444,199 shares of the firm’s stock in a transaction that occurred on Tuesday, September 20th. The stock was sold at an average price of $21.03, for a total transaction of $9,341,504.97. Following the completion of the transaction, the chief executive officer now directly owns 1,295,685 shares of the company’s stock, valued at approximately $27,248,255.55. The disclosure for this sale can be found here. 29.30% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the company. BlackRock Fund Advisors raised its stake in shares of Amphastar Pharmaceuticals by 105.3% in the third quarter. BlackRock Fund Advisors now owns 3,085,037 shares of the company’s stock worth $58,523,000 after buying an additional 1,581,978 shares during the period. Acadian Asset Management LLC raised its stake in shares of Amphastar Pharmaceuticals by 92.3% in the third quarter. Acadian Asset Management LLC now owns 1,573,986 shares of the company’s stock worth $29,858,000 after buying an additional 755,366 shares during the period. Vanguard Group Inc. raised its stake in shares of Amphastar Pharmaceuticals by 4.8% in the second quarter. Vanguard Group Inc. now owns 1,499,766 shares of the company’s stock worth $24,175,000 after buying an additional 68,048 shares during the period. BlackRock Institutional Trust Company N.A. raised its stake in shares of Amphastar Pharmaceuticals by 3.4% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 852,106 shares of the company’s stock worth $16,164,000 after buying an additional 27,993 shares during the period. Finally, Teachers Advisors LLC raised its stake in shares of Amphastar Pharmaceuticals by 5.0% in the third quarter. Teachers Advisors LLC now owns 541,260 shares of the company’s stock worth $10,268,000 after buying an additional 25,700 shares during the period. 37.97% of the stock is owned by hedge funds and other institutional investors.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Stock Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.